Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009;4(5):e5263.
doi: 10.1371/journal.pone.0005263. Epub 2009 May 6.

Atorvastatin reduces plasma levels of chemokine (CXCL10) in patients with Crohn's disease

Olof Grip  1 , Sabina Janciauskiene
Affiliations

Atorvastatin reduces plasma levels of chemokine (CXCL10) in patients with Crohn's disease

Olof Grip et al. PLoS One. 2009.

Abstract

Background: In Crohn's disease high tissue expression and serum levels of chemokines and their receptors are known to correlate with disease activity. Because statins can reduce chemokine expression in patients with coronary diseases, we wanted to test whether this can be achieved in patients with Crohn's disease.

Methodology/principal findings: We investigated plasma levels of chemokines (CCL2, CCL4, CCL11, CCL13, CCL17, CCL22, CCL26, CXCL8, CXCL10) and endothelial cytokines (sP-selectin, sE-selectin, sICAM-3, thrombomodulin) in ten Crohn's disease patients before and after thirteen weeks' daily treatment with 80 mg atorvastatin. Of the 13 substances investigated, only CXCL10 was found to be significantly reduced (by 34%, p = 0.026) in all of the treated patients. Levels of CXCL10 correlated with C-reactive protein (r = 0.82, p<0.01).

Conclusions/significance: CXCL10 is a ligand for the CXCR3 receptor, the activation of which results in the recruitment of T lymphocytes and the perpetuation of mucosal inflammation. Hence the reduction of plasma CXCL10 levels by atorvastatin may represent a candidate for an approach to the treatment of Crohns disease in the future.

Trial registration: (ClinicalTrials.gov) NCT00454545.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: Olof Grip gave paid lectures for Schering-Plough, MEDA and Ferring. Sabina Janciauskiene has received research grants from AstraZeneca.

Figures

Figure 1
Figure 1. Plasma levels of CXCL10/IP-10 in ten Crohn's disease patients at baseline and after thirteen weeks' treatment with 80 mg atorvastatin daily, *P<0.05.
See this image and copyright information in PMC

References

    1. Allen SJ, Crown SE, Handel TM. Chemokine: receptor structure, interactions, and antagonism. Annu Rev Immunol. 2007;25:787–820. - PubMed
    1. Sallusto F, Mackay CR, Lanzavecchia A. The role of chemokine receptors in primary, effector, and memory immune responses. Annu Rev Immunol. 2000;18:593–620. - PubMed
    1. Moser B, Willimann K. Chemokines: role in inflammation and immune surveillance. Ann Rheum Dis. 2004;63(Suppl 2):ii84–ii89. - PMC - PubMed
    1. Luster AD. The role of chemokines in linking innate and adaptive immunity. Curr Opin Immunol. 2002;14:129–135. - PubMed
    1. D'Ambrosio D, Iellem A, Bonecchi R, Mazzeo D, Sozzani S, et al. Selective up-regulation of chemokine receptors CCR4 and CCR8 upon activation of polarized human type 2 Th cells. J Immunol. 1998;161:5111–5115. - PubMed

Publication types

Associated data